We're happy to announce the #ArteraAI Prostate Test is the First-and-Only Predictive Test for Therapy Personalization in the 2024 @NCCN Guidelines for #ProstateCancer underscoring the importance of incorporating innovative tools for personalized treatment:

At #ASCO25, Prof. Nicholas James spoke with @urotoday about how an Artera's AI model helped identify high-risk patients (STAMPEDE) who benefited most from treatment intensification. Watch: #ArteraAI #ProstateCancer

ICYMI: Artera’s DIRECT-AI registry is tracking how the ArteraAI Prostate Test impacts treatment decisions and outcomes for localized prostate cancer. This study advances personalized care by monitoring metastasis, survival & treatment effectiveness:

We're headed to the @NationalMedAssn annual meeting next week! Reach out to set up a meeting with our Marketing Director, Michael Chang, to learn more about how #ArteraAI is making a difference in #prostatecancer care.

The team is headed to the Advanced Urology Institute 2025 Conference next week! We look forward to connecting with leaders in #Urology and sharing more about how #ArteraAI is shaping the future of #prostatecancer care. Reach out to us to set up a meeting. @AdvancedUrology

We’re proud to share that the @US_FDA has granted Breakthrough Device Designation to ArteraAI Prostate—the first and only AI-powered risk stratification tool for prostate cancer to receive this status. A step forward for personalized, risk-based care:

At #ASCO25, our CMO Dr. Tim Showalter spoke with @urotoday about how our #MMAI test predicts #prostatecancer distant metastasis rates and treatment response. Watch the full interview: #ArteraAI #ProstateCancer #PrecisionMedicine

How does Artera’s MMAI architecture work?. Our multimodal AI model analyzes both a patient’s biopsy image and their clinical data to predict therapeutic benefit—something conventional tools can’t do alone. 🔬. Watch the breakdown to see how it works:

RT @NCSilberman: Looking for Software Engineers to join @arteraAI 's platform engineering team. You'll be responsible for owning the AWS co….

That’s a wrap on #ABSBrachy2025 in Nashville!. It was great to connect with the brachytherapy community and sharing how Artera is advancing AI in #prostatecancer care. Until next time! 👋

Prof. Nick James of @ICR_London joins The @Uromigos Podcast to discuss #ArteraAI Prostate Test results from #ASCO25, showing how AI can predict which high-risk patients benefit from adding #abiraterone to ADT. 🎧 Listen:

Did you know: The ArteraAI Prostate Test provides therapy-relevant insights across the spectrum of localized prostate cancer—guiding decisions from active surveillance to short-term ADT to adjunctive abiraterone therapy. Learn more:

Want to hear from current #ArteraAI Prostate Test users Drs. Nicolas Zouain and Kenneth Nepple on how to utilize the test results to inform clinical decision making? . Watch the recording of our latest webinar: #prostatecancer #precisionmedicine

RT @urotoday: Multimodal AI test predicts #ProstateCancer metastasis and treatment response. @TimShowalter1 @arteraAI joins @l_ballas @Ceda….

RT @diagnexia: We are excited to be at BAUS 2025 next week in Manchester, June 16–18!.Come visit Diagnexia & @arteraAI at our joint booth t….

Artera is proud to announce the launch of DIRECT-AI, a first-of-its-kind study assessing the real-world impact of the ArteraAI Prostate Test on treatment decisions and long-term outcomes for localized prostate cancer patients:

Mental well-being is a critical, often overlooked part of the cancer journey. In @PsychToday, Dr. Tim Showalter explores how AI-powered tools like the ArteraAI Prostate Test can reduce anxiety by bringing clarity to care: . #MentalHealthAwareness #MHAM

We’re proud to wear blue in support of #MensHealthWeek and #WearBlueDay. With prostate cancer ranking as the second most common cancer in U.S. men according to @AmericanCancer, it’s a powerful reminder of the value of early detection, awareness, and personalized care.

We’re headed to NYC this June for the @nyulangone Therapeutic Radiology Spring Symposium!. Excited to connect and share how Artera is advancing AI-driven tools in prostate cancer care. #RadiationOncology #ProstateCancer #ArteraOnTheGo

The #ArteraAI Prostate Test is now available in New York! . With our newly granted lab license, we now offer nationwide access to AI-powered insights for #prostatecancer care—helping 15,000+ patients diagnosed in NY each year. Read the full announcement:

The Artera team had a great time at #ASCO25— it was a blast to see the excitement around our data presentations and share how AI is driving progress in #prostatecancer care. Thanks to everyone who stopped by and made the week in Chicago one to remember!